GlassScriptPhysician profile
Emily Rench
NPI 1013386903
$1,186.33
in general payments reported to CMS, 2019-2025
17 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.99 · 2023: $390 · 2024: $457 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065 · Education: $96.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.53 |
| Education | $96.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $302.62 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $259.59 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $140.31 | 2024 | Wegovy |
| Phathom Pharmaceuticals, INC. | $119.70 | 2025 | Voquezna |
| Abbvie INC. | $90.68 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.96 | 2023-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $49.07 | 2025 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.79 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $21.12 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $18.85 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $18.09 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $16.90 | 2025 | Trelegy Ellipta |
| Lundbeck LLC | $15.51 | 2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $14.74 | 2023 | Invega Trinza, Invega Sustenna |
| Esperion Therapeutics, INC. | $14.56 | 2025 | Nexletol |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.51 | 2025 | Breztri |
| Neurocrine Biosciences, INC. | $13.33 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Rench listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.